The influenza virus Ml mRNA has two alternative 5' splice sites: a distal 5' splice site producing mRNA3 that has the coding potential for 9 amino acids and a proximal 5' splice site producing M2 mRNA encoding the essential M2 ion-channel protein. Only mRNA3 was made in uninfected cells transfected with DNA expressing Ml mRNA. Similarly, using nuclear extracts from uninfected cells, in vitro splicing of Ml mRNA yielded only mRNA3. Only when the mRNA3 5' splice site was inactivated by mutation was M2 mRNA made in uninfected cells and in uninfected cell extracts. In influenza virus-infected cells, M2 mRNA was made, but only after a delay, suggesting that newly synthesized viral gene product(s) were needed to activate the M2 5' splice site. We present strong evidence that these gene products are the complex of the three polymerase proteins, the same complex that functions in the transcription and replication of the viral genome. Gel shift experiments showed that the viral polymerase complex bound to the 5' end of the viral Ml mRNA in a sequence-specific and cap-dependent manner. During in vitro splicing catalyzed by uninfected cell extracts, the binding of the viral polymerase complex blocked the mRNA3 5' splice site, resulting in the switch to the M2 mRNA 5' splice site and the production of M2 mRNA.
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Alternative splicing of pre-mRNA plays an important role in regulating the expression of genes during development, differentiation, and virus infection (1, 2) . Insight into alternative splicing mechanisms has come from the identification of proteins that regulate the choice of alternative splice sites. Some of these proteins apparently serve this specialized function only, e.g., the Drosophila melanogaster sex lethal (Sxl) protein controls the choice of 3' splice sites during the splicing of both Sxl and transformer (tra) pre-mRNAs (2) (3) (4) (5) (6) (7) . Other proteins function in constitutive as well as alternative splicing: the constitutive splicing factors, the SR proteins, also function in the selection of 5' splice sites in some pre-mRNAs (8) (9) (10) (11) (12) . High concentrations of SR proteins favor the use of the proximal (downstream) 5' splice site.
The alternative splicing of the Ml mRNA of influenza A virus exhibits several distinctive features. There are two alternative 5' splice sites. The distal 5' splice site, which closely fits the consensus 5' splice site sequence, is used when the Ml gene is transfected into uninfected cells (13) (14) (15) . The resulting mRNA, termed mRNA3, has a reading frame for only a 9-amino acid peptide. The proximal 5' splice site, which does not fit the consensus as well, is not detectably used when the Ml gene is transfected into uninfected cells (refs. 14 and 15 and the present study). However, this proximal 5' splice site is used in influenza virus-infected cells, generating the M2 mRNA encoding the essential M2 ion-channel protein (16, 17) . How is the M2 mRNA 5' splice site activated in virus-infected cells? Here we demonstrate that the complex of the three viral
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polymerase proteins that function in processes unrelated to splicing, namely, the transcription and replication of the viral genome (18) , are responsible for the activation of the M2 mRNA 5' splice site.
MATERIALS AND METHODS
Transfection and Influenza Virus Infection. Full-length wild-type and mutated Ml DNAs were inserted into pBC12 plasmids, which were transfected into 293 cells by using the calcium phosphate method (15, 19 In Vitro Splicing Assays. The Ml DNA containing a large deletion in the intron (see Fig. 2A (15) (16) (17) 27) , contain [10] [11] [12] [13] host-coded nucleotides at their 5' ends as a result of capped RNA-primed initiation of viral RNA transcription (18, 28) (Fig. 1A) . The mRNA3 5' splice site is 11 nt downstream from the beginning of the viral-encoded sequence, i.e., 21-24 nt from the 5' end of the mRNA. The M2 mRNA 5' splice site occurs 40 nt downstream from the mRNA3 5' splice site. The mRNA3 5' splice site more closely fits the consensus 5' splice site than the M2 mRNA 5' splice site, which has a cytidine rather than a guanosine at the 3' end of the 5' exon.
Most (14, 15) , but not all (29), previous studies indicated that only the mRNA3 5' splice site, but not the M2 mRNA 5' splice site, is used in uninfected cells. To clarify this issue, a plasmid containing the Ml DNA sequence under the control of the cytomegalovirus promoter was transfected into 293 cells. The Ml mRNA transcribed from this sequence contained 13 nt 5' to the viral Ml sequence and would thus be similar to the Ml mRNA synthesized in influenza virus-infected cells. At 40 h after transfection, the total RNA was assayed for the presence of mRNA3 and M2 mRNA by using RT-PCR. The doublestranded DNAs derived from mRNA3 and M2 mRNA should be 111 and 151 nt long, respectively. After PCR the resulting double-stranded DNAs were resolved by agarose gel electrophoresi § (Fig. 1B) . The double-stranded DNA generated from the RNA from the transfected cells had the mobility expected of mRNA3 (lane 2), and sequence analysis verified that this was indeed the DNA amplified from mRNA3 (data not shown). No DNA corresponding to M2 mRNA was detected.
To determine whether the M2 5' splice site could be recognized in uninfected cells, the mRNA3 5' splice site in the Ml DNA plasmid was inactivated by mutating the guanosine at position + 12 in the Ml sequence to a cytidine. The RT-PCR detected the production of M2 mRNA in cells transfected by this plasmid (Fig. 1B, lane 3) . Thus, the cellular splicing machinery was capable of recognizing the M2 5' splice site, but only when the mRNA3 5' splice site was absent (15) .
The time course of MI mRNA splicing to form mRNA3 and M2 mRNA in infected cells was determined by using the RT-PCR assay (Fig. 1B, lanes 4-15) . The first splicing product of Ml mRNA was detected at 1.0 h after infection (lane 5). Only mRNA3 and not M2 mRNA was produced between 1.0 h and 1.75 h after infection (lanes 5-8). The production of M2 mRNA was delayed until 2.0 h after infection (lane 9). At subsequent time points, both M2 mRNA and mRNA3 were present (lanes [10] [11] [12] [13] [14] [15] . The delay in the appearance of M2 mRNA suggested that some newly synthesized viral gene product was needed to activate the M2 5' splice site.
In Vitro Splicing of Ml mRNA. As a prerequisite for determining the mechanism by which the mRNA3 5' splice site is activated in infected cells, we established conditions under which the splicing of Ml mRNA occurred in vitro. By using nuclear extracts from uninfected HeLa cells, Ml mRNA splicing was achieved only when deletions were made in the middle of the intron and at the 3' end of the 3' exon, resulting in a 333-nt precursor ( Fig. 2A ). This Ml mRNA construct was spliced, albeit inefficiently, to produce mRNA3 (Fig. 2B, The RNA denoted as mRNA3 is actually the mRNA generated by using the mRNA3 5' splice site and the SV40 3' splice site.
after RT-PCR amplification (data not shown). No M2 mRNA was detected. The inefficient splicing was largely due to sequences in the 3' half of the MI DNA. When the 3' half of the MI mRNA construct was replaced by the corresponding region of an SV40 early pre-mRNA ( Fig. 2A) , splicing was stimulated >20-fold (Fig. 2C) . Again, only the mRNA3 and not the M2 mRNA 5' splice site was used, as was the case for the MI mRNA construct itself. The uninfected cell nuclear extract was capable of using the M2 5' splice site only when the mRNA3 5' splice site in the Ml mRNA construct was inactivated by mutation (Fig. 2B, lane 4) . These results are the same as those obtained in vivo.
Identification of the Viral Proteins that Cause the Activation of the M2 mRNA 5' Splice Site. Recent experiments from others have shown that the complex of the three viral polymerase proteins (PB1, PB2, and PA) binds to the first 11 or 12 nt at the 5' end of both virion RNA and its complementary RNA (26, 27) , but it was not known whether this complex would bind to viral mRNA, which contains an additional 10-13 nt 5' to the virus-encoded sequence. To test this possibility, we carried out gel shift experiments by using a partially purified viral polymerase complex and a 58-nt RNA corresponding to the 5'-terminal virus-encoded sequence of Ml mRNA plus an additional 13 nt 5' to the Ml sequence (Fig. 3A) . Increasing amounts of the viral polymerase complex bound increasing amounts of this MI-specific RNA (Fig. 3B, lanes 1-4) . This binding was sequence specific: when the sequence of the first 6 MI-specific nucleotides was changed (mut6, Fig. 3A) , the binding of the viral polymerase complex was reduced 10-to 20-fold (Fig. 3B, lanes 5-8) . This binding was also dependent on the presence of a 5'-terminal methylated cap structure. The 58-nt Mi-specific RNA containing a GpppG 5' end bound to the viral polymerase complex 10-fold less efficiently than the same RNA containing a m7GpppGm 5' end (Fig. 3C ).
To determine whether the binding of the viral polymerase complex to the 5' end of Ml mRNA affects the choice of 5' splice sites, increasing amounts of the viral polymerase complex were bound to the 333-nt wild-type Ml precursor (see Fig.  2A ) in a short (15 min) preincubation, followed by a 2-h splicing reaction catalyzed by uninfected cell nuclear extracts (Fig. 4A) . The binding of the viral polymerase complex caused a dramatic switch from the production of mRNA3 to the production of M2 mRNA by splicing (compare lanes 3-6 to lanes 1 and 2). The switch to the M2 5' splice site was dependent on the preservation of the Ml mRNA binding site for the viral polymerase complex. This was established by using a 333-nt Ml precursor that contained the same 5'-terminal mutations that severely reduced polymerase binding (see mut6, Fig. 3 ). The mutated Ml mRNA was spliced to form mRNA3, but preincubation of this mRNA with increasing amounts of the viral polymerase complex did not cause a switch to the production of M2 mRNA (Fig. 4B ).
DISCUSSION
Our results indicate that the choice of alternative 5' splice sites in influenza virus Ml mRNA is regulated by the viral polymerase complex (Fig. 5) . In uninfected cells, the distal mRNA3 5' splice site is exclusively used, thereby generating mRNA3. This splice site continues to be used at early times of infection, until sufficient amounts of the polymerase complex are synthesized. These polymerase complexes bind to the 5'-terminal Mi-specific sequences in Ml mRNAs plus the 5'-terminal cap structure, thereby blocking the mRNA3 5' splice site that is located at position 11 in the Ml virus-specific sequence. The cellular splicing machinery then switches to the downstream (proximal) M2 5' splice site. Consequently, after a delay of -1 h, the production of M2 mRNA commences.
M2 mRNA encodes the M2 ion-channel protein that functions during the uncoating of the virus (16, 17) . The M2 protein associated with the incoming virus particles permits ions to enter the virions, leading to a lowering of the pH (17, 30) . This apparently dissociates the viral nucleocapsids from viral matrix proteins (30, 31) . Newly synthesized M2 proteins do not participate in this uncoating but, rather, are needed for incorporation into progeny virus particles. The requirement for prior synthesis of viral polymerase complexes to activate the M2 5' splice site and hence the production of M2 mRNA ensures that the M2 protein is made only when it is needed. It may also be that the presence of increased amounts of the M2 protein at early times would actually be deleterious to early virus-specitic events. Fig. 2A ) (100,000 cpm, 1.6 pmol) was incubated with the indicated amounts of the viral polymerase complex (3P) at 20°C for 15 min. HeLa nuclear extract (25 jil) was added, and splicing reaction mixtures were incubated for 2 h at 30°C. RNA was analyzed by electrophoresis on 7% denaturing gels. (B) Labeled MI precursor containing the mut6 mutations at its 5' end was substituted for the wild-type Ml precursor.
The primary role of the viral polymerase complex is the transcription and replication of the viral genome (18) . During transcription this complex cleaves capped RNA fragments (10-13 nt) from host nuclear pre-mRNAs and mRNAs and then utilizes these fragments as primers to catalyze viral mRNA synthesis. The resulting viral mRNAs do not participate in viral RNA replication. For viral RNA replication, the polymerase complex acquires the ability to catalyze the unprimed copying of virion RNA into its complement and the subsequent unprimed copying of the complement into virion RNA. Recent experiments indicate that the polymerase complex containing the three polymerase proteins binds to the 5' end of the virus-specific RNA (virion RNA or its complement) that is to be copied or transcribed (26, 27) . The binding site encompasses the first 11 or 12 5'-terminal nucleotides. After binding to the 5' end of virion RNA the viral polymerase complex acquires the cap-binding activity but not the endonucleolytic activity required for transcription initiation (27 polymerase complex to Ml mRNA. Hence, as a consequence of the overlap, or close proximity, of the mRNA3 5' splice site and the polymerase binding site, the virus utilizes the polymerase complex to control the alternative splicing of Ml mRNA as well as to catalyze transcription and replication. In addition, because the polymerase complex would be expected to bind to the 5' ends of all the viral mRNAs, this binding may also serve other roles.
Influenza virus utilizes viral rather than cellular proteins to control the choice of 5' splice sites in Ml mRNA. The cellular ASF/SF2 splicing factor, an SR protein, has been shown to favor the use of proximal 5' splice sites (8, 9) . However, this factor did not affect the choice of Ml mRNA 5' splice sites (data not shown). This may be due at least in part to the close proximity of the mRNA3 and M2 mRNA 5' splice sites, as it has been found that ASF/SF2 functions in 5' splice site switching only when the two 5' splice sites are separated by >40 nt (32) .
Alternative splicing occurs in many systems, including cells infected by various animal viruses (1, 2). The only previous evidence for the role of virus-specific proteins in alternative splicing during infection has been in the adenovirus system, where two proteins encoded in the E4 region of the viral genome have been implicated in the regulation of pre-mRNA splicing (33) . The present study of the influenza virus system elucidates the mechanism by which specific viral proteins, those in the polymerase complex, directly regulate the alternative splicing of a particular viral mRNA, the Ml mRNA. This role of the influenza viral polymerase complex in alternative splicing can be compared to the role of the Sxl protein in the alternative splicing of tra pre-mRNA during sex determination in Drosophila (4-7). The Sxl protein blocks the constitutive 3' splice site, and the splicing system then switches to an alternative 3' splice site, thereby resulting in a mRNA encoding the tra protein. This is similar to the situation when the alternative influenza viral M2 mRNA 5' splice site is used after the binding of the viral polymerase complex to the constitutive mRNA3 5' splice site. This alternative M2 mRNA 5' splice site was used very efficiently when the mRNA3 5' splice site was blocked by the viral polymerase complex, thereby generating significant amounts of M2 mRNA. This is likely to be of advantage to the virus. It will be important to determine how the splicing machinery utilizes the M2 mRNA 5' splice site so efficiently under these conditions. We thank Mark Krystal for providing us with invaluable guidance concerning the purification and properties of the influenza virus polymerase complex. We thank Helen F. Pirrello for typing this manuscript. This investigation was supported by a National Institutes of Health grant (AI11772, merit award) to R.M.K.
